Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?

Walid Shaib, Daniel Goldstein, Bassel F. El-Rayes*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Colorectal cancer (CRC) is the third most common cancer diagnosis and cause of cancer-related death in the USA. It accounts for more than one million cases diagnosed each year worldwide. In the past 10 years, new drugs have been approved, but the survival times are still modest. Alternative therapeutic strategies are clearly needed. A large number of tumor antigens and epitopes recognized by cytotoxic T lymphocytes (CTLs) have been identified in CRC. Cancer vaccines, designed to activate immune effectors (T cells and antibodies), to prevent recurrence, or to treat advanced cancers, have demonstrated clinical benefit in melanoma, prostate cancer, and lymphoma. Immunotherapy that targets tumor-associated antigens (TAAs) on cancer cells or tumor stroma is under investigation. This review discusses CRC immune responsiveness, current status of CRC vaccines, challenges, and future directions. New therapeutic modalities hold a promise to improve the patient’s clinical outcome.

Original languageEnglish
Pages (from-to)477-486
Number of pages10
JournalCurrent Colorectal Cancer Reports
Issue number4
StatePublished - Dec 2014
Externally publishedYes


FundersFunder number
AVEO Pharmaceuticals
Synta Pharmaceuticals
Bristol-Myers Squibb
Kyowa Hakko Kirin
Oncolytics Biotech


    • Colorectal cancer
    • Peptide vaccines


    Dive into the research topics of 'Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?'. Together they form a unique fingerprint.

    Cite this